Organogenesis Holdings Inc.

Organogenesis Holdings Inc., trading under the ticker ORGO on Nasdaq, completed its business combination with Avista Healthcare Public Acquisition Corp (AHPA) in December 2018, as reported in the 8-K filed on December 10, 2018. AHPA was sponsored by Avista Capital Partners and conducted its initial public offering in 2016, targeting the healthcare sector with a focus on regenerative medicine and advanced wound care. The transaction brought Organogenesis, a commercial-stage regenerative medicine company specializing in wound care biologics and surgical reconstruction products, into the public markets through the de-SPAC process. The combined company operates within the broader medical technology and specialty healthcare segment. Visit SpacDesk and sign up for full data, filings, and analytics on this and hundreds of other SPAC transactions.